Corcept Therapeutics (CORT) Tops Q3 EPS by 3c, provides guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.71 --0%
Revenue Growth %: +12.1%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +12.1%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.16, $0.03 better than the analyst estimate of $0.13. Revenue for the quarter came in at $207.6 million versus the consensus estimate of $218.53 million.
GUIDANCE:
Corcept Therapeutics sees FY2025 revenue of $800-850 million, versus the consensus of $852.7 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- RBC Capital Starts Centene (CNC) at Sector Perform
- Baker Hughes wins long-term service deal for Nigeria gas plant
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
